Post-glucose load plasma α-dicarbonyl concentrations are increased in individuals with impaired glucose metabolism and type 2 diabetes: The CODAM study

Diabetes Care

Volumn 38, Issue 5, 2015, Pages 913-920

  Maessen, Dionne E ^a,b   Hanssen, Nordin M ^a,b   Scheijen, Jean L ^a,b   Van Der Kallen, Carla J ^a,b   Van Greevenbroek, Marleen M ^a,b   Stehouwer, Coen D ^a,b   Schalkwijk, Casper G ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DICARBONYL DERIVATIVE; 3 DEOXYGLUCOSONE; GLUCOSE; GLYOXAL; HEMOGLOBIN A1C; METHYLGLYOXAL; 3-DEOXYGLUCOSONE; DEOXYGLUCOSE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DIABETIC ANGIOPATHY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RISK ASSESSMENT; SEX RATIO; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANALOGS AND DERIVATIVES; ATHEROSCLEROSIS; BLOOD; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POSTPRANDIAL STATE;

ATHEROSCLEROSIS; BLOOD GLUCOSE; CHROMATOGRAPHY, LIQUID; CROSS-SECTIONAL STUDIES; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; GLYOXAL; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; MALE; MASS SPECTROMETRY; MIDDLE AGED; POSTPRANDIAL PERIOD; PYRUVALDEHYDE;

EID: 84958676725     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2605     Document Type: Article

References (40)

1. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev 2013;93:137-188
2. de Vegt F, Dekker JM, Ruhé HG, et al. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999;42:926-931
3. Beisswenger P, Heine RJ, Leiter LA, Moses A, Tuomilehto J. Prandial glucose regulation in the glucose triad: emerging evidence and insights. Endocrine 2004;25:195-202
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
6. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002;25:275-278
7. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987;36:689-692
8. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stamler J. Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997;20:163-169
9. DECODE Study Group; European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999;354:617-621
10. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233-240
11. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360-367
12. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583
13. Cavalot F, Petrelli A, Traversa M, et al. Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga Diabetes Study. J Clin Endocrinol Metab 2006;91:813-819
14. Brouwers O, Niessen PM, Miyata T, et al. Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. Diabetologia 2014;57:224-235
15. Giacco F, Du X, D'Agati VD, et al. Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes 2014;63:291-299
16. Berner AK, Brouwers O, Pringle R, et al. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia 2012;55:845-854
17. Duran-Jimenez B, Dobler D, Moffatt S, et al. Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes 2009;58:2893-2903
18. Bierhaus A, Fleming T, Stoyanov S, et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nat Med 2012;18:926-933
19. Tikellis C, Pickering RJ, Tsorotes D, et al. Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. Diabetes 2014;63:3915-3925
20. Beisswenger PJ, Howell SK, O'Dell RM, Wood ME, Touchette AD, Szwergold BS. alpha-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 2001;24:726-732
21. Du H, van der A DL, van Bakel MM, et al. Glycemic index and glycemic load in relation to food and nutrient intake and metabolic risk factors in a Dutch population. Am J Clin Nutr 2008;87:655-661
22. Hanssen NM, Engelen L, Ferreira I, et al. Plasma levels of advanced glycation endproducts Nε-(carboxymethyl)lysine, Nε-(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies. J Clin Endocrinol Metab 2013;98:E1369-E1373
23. Scheijen JL, Schalkwijk CG. Quantification of glyoxal, methylglyoxal and 3-deoxyglucosone in blood and plasma by ultra performance liquid chromatography tandem mass spectrometry: evaluation of blood specimen. Clin Chem Lab Med 2014;52:85-91
24. Allison DB, Paultre F, Maggio C, Mezzitis N, Pi-Sunyer FX. The use of areas under curves in diabetes research. Diabetes Care 1995;18:245-250
25. van Greevenbroek MM, Jacobs M, van der Kallen CJ, et al. The cross-sectional association between insulin resistance and circulating complement C3 is partly explained by plasma alanine aminotransferase, independent of central obesity and general inflammation (the CODAM study). Eur J Clin Invest 2011;41:372-379
26. Levey AS, Stevens LA, Schmid CH, et al, .; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612
27. Jacobs M, van Greevenbroek MM, van der Kallen CJ, et al. Low-grade inflammation can partly explain the association between the metabolic syndrome and either coronary artery disease or severity of peripheral arterial disease: the CODAM study. Eur J Clin Invest 2009;39:437-444
28. El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008;205:2409-2417
29. Brouwers O, Niessen PM, Ferreira I, et al. Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J Biol Chem 2011;286:1374-1380
30. Kang Y, Edwards LG, Thornalley PJ. Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA G1 growth arrest and induction of apoptosis. Leuk Res 1996;20:397-405
31. Kalapos MP. Where does plasma methylglyoxal originate from? Diabetes Res Clin Pract 2013;99:260-271
32. Schalkwijk CG, van Bezu J, van der Schors RC, Uchida K, Stehouwer CD, van Hinsbergh VW. Heat-shock protein 27 is a major methylglyoxal-modified protein in endothelial cells. FEBS Lett 2006;580:1565-1570
33. Thornalley PJ. The glyoxalase system in health and disease. Mol Aspects Med 1993;14:287-371
34. Rabbani N, Thornalley PJ. Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 2011;22:309-317
35. Vora J, Bain SC, Damci T, et al. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. Diabetes Metab 2013;39:6-15
36. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014;371:313-325
37. Williams ME, Bolton WK, Khalifah RG, Degenhardt TP, Schotzinger RJ, McGill JB. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007;27:605-614
38. Tanimoto M, Gohda T, Kaneko S, et al. Effect of pyridoxamine (K-163), an inhibitor of advanced glycation end products, on type 2 diabetic nephropathy in KK-A(y)/Ta mice. Metabolism 2007;56:160-167
39. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939-950
40. Wolever TM, Chiasson JL, Csima A, et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998;21:336-340